Gold prices hover near 6-week high amid softer dollar, Fed rate cut bets
Johnson & Johnson Innovation - JJDC, Inc., a ten-percent owner of CVRx , Inc. (NASDAQ:CVRX), reported selling 2,700 shares of common stock for $27,132, according to a Form 4 filing with the Securities and Exchange Commission. The sales occurred in two transactions.
On November 21, 2025, the entity sold 500 shares at $10.00 each. Then, on November 24, 2025, it sold 2,200 shares in multiple transactions at prices ranging from $10.00 to $10.10.
Following these transactions, Johnson & Johnson Innovation - JJDC, Inc. indirectly holds 4,047,198 shares of CVRx. The filing was signed by Marc Larkins, Secretary, on behalf of Johnson & Johnson, and by Jill McManus, Assistant Treasurer, on behalf of Johnson & Johnson Innovation - JJDC, Inc.
In other recent news, CVRx Inc. reported its third-quarter 2025 financial results, with revenue reaching $14.7 million, marking a 10% year-over-year growth. This figure exceeded the estimates from both Cantor Fitzgerald and Canaccord Genuity, as well as the FactSet consensus. The company’s earnings per share (EPS) showed a loss of $0.49, slightly better than the anticipated loss of $0.50. Following these results, Cantor Fitzgerald increased its price target for CVRx from $11 to $13, maintaining an Overweight rating. Canaccord Genuity also raised its price target from $9 to $11, keeping a Buy rating. Additionally, the Centers for Medicare & Medicaid Services (CMS) finalized its 2026 payment rule, ensuring payment stability for CVRx’s Barostim procedure. These developments indicate continued analyst confidence in the company, despite the stock’s decline in after-hours trading.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.